เอกสารอ้างอิง
[1]. กองโรคติดต่อทั่วไป กรมควบคุมโรค กระทรวงสาธารณะสุข. แนวทางการให้วัคซีนโควิด 19 ใน สถานการณ์การระบาด ปี 2564 ของประเทศไทย ฉบับปรับปรุง ครั้งที่ 2 สิงหาคม 2564. พิมพ์ครั้งที่ 2. กรุงเทพมหานคร: บริษัท ทีเอส อินเตอร์พริ้นท์ จำกัด; 2564. :5, 59-61.
[2]. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™): interim guidance, first issued 10 February 2021, updated 21 Apr. 2021, last updated 30 Jul. 2021. 2021;[12 screens]. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1. Access Nov. 13, 2021.
[3]. AstraZeneca Canada Inc. AstraZeneca COVID-19 Vaccine Product Monograph, revised September 15,2021. 2021;[27 screens]. Available at: https://covid-vaccine.canada.ca/covishield/product-details. Access Nov. 13, 2021.
[4]. Katherine L. How Effective Are COVID-19 Vaccines in Immunocompromised People. 2021. Available at : https://asm.org/Articles/2021/August/How-Effective-Are-COVID-19-Vaccines-in-Immunocompr. Access : Nov. 16, 2021.
[5]. Ruth JH. How Immunosuppression May Affect COVID-19 Vaccine Response.2021. Available at: https://www.the-rheumatologist.org/article/how-immunosuppression-may-affect-covid-19-vaccine-response/3/?singlepage=1 Access : Nov. 16, 2021.
[6]. Centers for Disease Control and Prevention. COVID-19 Vaccines for Moderately to Severely Immunocompromised People. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html#anchor_1630089719053. Access : Nov. 16, 2021.
[7]. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Interim guidance on booster COVID-19 vaccine doses in Canada, Published: October 29, 2021 Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/statement-guidance-booster-doses/statement-guidance-booster-doses.pdf. Access : Nov. 21, 2021.
[8]. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, Previous Updates : November 17, 2021 Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-covid19-vax-booster. Access : Nov. 21, 2021.
[9]. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv [Preprint]. 2021 Apr. 9, 2021.
[10]. Prendecki M, Clarke C, Edwards H, McIntyre S, Mortimer P, Gleeson S,et al . Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann. Rheum. Dis. 2021 Oct.;80(10): 1322-1329.
[11]. Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann. Rheum. Dis. 2021 Oct.;80(10): 1357-1359.
[12]. Caminati M, Guarnieri G, Batani V, Scarpieri E, Finocchiaro A, Chieco-Bianchi F, et al. COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control. Vaccines (Basel). 2021 Aug. 4;9(8): 853.
[13]. Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al .Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N. Engl. J. Med. 2021 Sep. 23;385(13): 1244-1246.
[14]. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021 Aug. 12;385(7): 661-662.
[15]. Samadhi P, Sutthiwan T, Benjaporn B. Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac. medRxiv [Preprint]. 2021 Sep. 28, 2021.